AMRX Q3 2018 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$476M+87.1% YoY

Gross Profit

$200M42.0% margin

Operating Income

$75M15.6% margin

Net Income

$7M1.5% margin

EPS (Diluted)

$0.05

QoQ Revenue Growth

+15.2%

Cash Flow

Operating Cash Flow

$62M

Free Cash Flow

$25M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$3.7B

Stockholders' Equity

$501M

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$476M	$255M	+87.1%
Gross Profit	$200M	$135M	+48.2%
Operating Income	$75M	$79M	-5.3%
Net Income	$7M	$27M	-74.0%

Revenue Segments

Yuvafem-Estradiol

$48M30%

Rytary Family

$33M21%

Epinephrine Auto-Injector Family (Generic Adrenaclick)

$30M19%

Diclofenac Sodium Gel

$26M16%

Aspirin;Dipyridamole ER Capsul

$23M14%